Cytheris

Ogd2 Pharma

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Nantes Université

Institut De Cancerologie De L'ouest

Brigitte Assouline

Michel Christian Morre

Anne Gregoire

Iann Rance

Corinne Breque

Jean-Marc Le Doussal

Michel Morre

Mickaël Terme

Mylene Dorvillius

Denis Cochonneau

Stéphane Birkle

Pierre Cortez

Sébastien Faraj

Julien Fleurence

Pierre Demol

Stéphanie Beq

Thérèse Croughs

Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.

Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs

Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id no 112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id no 76; and its use in diagnostics and therapy.

Humanized antibody against O-acetylated GD2 ganglioside (OAcGD2)

The present invention relates to new and improved interleukin-7 polypeptides, as well as compositions comprising the same, their preparation and uses. The invention more particularly relates to hyperglycosylated IL-7 polypeptides having improved properties, as well as their manufacture and therapeutic uses. The invention also discloses novel IL-7 polypeptides having modified amino acid sequences containing artificially created glycosylation site(s), as well as corresponding nucleic acid molecules, vectors and recombinant host cells. The invention also relates to the use of such polypeptides, cells or nucleic acids for curative or preventive treatment of mammalian subjects, including human subjects.

Hyperglycosylated mammalian IL-7 IgG conjugate composition

Hyperglycosylated IL-7, preparation and uses

Glycosylated IL-7, preparation and uses

The present invention relates, generally, to the fields of immunology and molecular biology. The invention discloses, more particularly, new and improved interleukin-7 drug substances, corresponding specific immunoreactive antibodies, as well as compositions comprising the same, their preparation and uses. The invention also discloses methods to characterize the impurity profile of a r-hIL-7 drug substance used for therapeutic purpose, as well as optimized nucleotide sequences encoding mammalian IL-7, recombinant expression vectors and methods for preparing and purifying said polypeptides. The present invention stems from the unexpected discovery that the long term activity of recombinant IL-7 is mostly expressed by a specific conformer and that other conformers, potential product-related substances, product-related impurities, and process-related impurities, which would normally be included in the specification of the drug substance and/or drug product, although bioactive, should be strictly minimized because they are able to trigger an immune reaction against the desired IL-7 molecule.

IL-7 drug substance, composition, preparation and uses

Growing community of inventors

Courbevoie, France

Brigitte Assouline